Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.75
-0.0300-1.69%
Post-market: 1.770.0195+1.11%19:59 EDT
Volume:4.18M
Turnover:7.39M
Market Cap:65.49M
PE:-1.19
High:1.84
Open:1.81
Low:1.73
Close:1.78
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:0.46
T/O Rate:23.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.58
PE(LYR):-1.30

Loading ...

Tenax Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jun 13

Tenax Therapeutics price target raised to $50 from $20 at Piper Sandler

TIPRANKS
·
Jun 12

Tenax Therapeutics Announces Results of 2026 Annual Meeting

TIPRANKS
·
Jun 05

Tenax Therapeutics shareholders ratified Cherry Bekaert as independent auditor for 2026

Reuters
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)

TIPRANKS
·
Jun 01

LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)

TIPRANKS
·
May 16

Tenax Therapeutics CFO Thomas R. Staab II files initial beneficial ownership statement

Reuters
·
May 14

Tenax Therapeutics: Buy Rating Reiterated with $27 Price Target Unchanged on Compelling Phase 3 Opportunity

TIPRANKS
·
May 13

Tenax Therapeutics reports Q1 EPS (35c), consensus (40c)

TIPRANKS
·
May 12

Tenax Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Tenax Therapeutics Q1 Net Income USD -15.716 Million

Reuters
·
May 12

Tenax Therapeutics Q1 net loss widens on higher R&D costs

Reuters
·
May 12

Tenax Therapeutics Q1 EPS $(0.35) Beats $(0.58) Estimate

Benzinga Earnings
·
May 12

Tenax Therapeutics Q1 EPS USD -0.35

THOMSON REUTERS
·
May 12

Tenax Therapeutics Q1 Operating Income USD -16.573 Million

THOMSON REUTERS
·
May 12

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)

TIPRANKS
·
May 10

Tenax Therapeutics awards inducement options for 657,500 shares to new hires

Reuters
·
May 09

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 09

Tenax Therapeutics appoints Timothy Healey chief commercial officer

Reuters
·
May 04